Drug Information

Drug General Information
Drug ID
D08LRV
Former ID
DNCL002836
Drug Name
BGP-15
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [526305], [531807]
Company
N-Gene Research Laboratories
Structure
Download
2D MOL

3D MOL
Formula
C14H24Cl2N4O2
Canonical SMILES
C1CCN(CC1)CC(CON=C(C2=CN=CC=C2)N)O.Cl.Cl
InChI
1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
InChIKey
ISGGVCWFTPTHIX-UHFFFAOYSA-N
PubChem Compound ID
9884807
PubChem Substance ID
14851985, 14900862, 24171659, 45631748, 76411902, 134223363, 162248763, 163404458, 163846800, 172648828, 172907825, 189052916, 204366311, 229117979, 252214978
Target and Pathway
Target(s) Poly ADP ribose polymerase (PARP) Target Info Modulator [526305], [531807]
References
Ref 526305BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol. 2002 Mar 15;63(6):1099-111.
Ref 531807BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
Ref 526305BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol. 2002 Mar 15;63(6):1099-111.
Ref 531807BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.